| __timestamp | Alnylam Pharmaceuticals, Inc. | Cytokinetics, Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 17268000 |
| Thursday, January 1, 2015 | 60610000 | 19667000 |
| Friday, January 1, 2016 | 89354000 | 27823000 |
| Sunday, January 1, 2017 | 199365000 | 36468000 |
| Monday, January 1, 2018 | 382359000 | 31282000 |
| Tuesday, January 1, 2019 | 479005000 | 39610000 |
| Wednesday, January 1, 2020 | 588420000 | 52820000 |
| Friday, January 1, 2021 | 620639000 | 96803000 |
| Saturday, January 1, 2022 | 770658000 | 177977000 |
| Sunday, January 1, 2023 | 795646000 | 173612000 |
| Monday, January 1, 2024 | 975526000 |
Data in motion
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. Alnylam Pharmaceuticals, Inc. and Cytokinetics, Incorporated have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by approximately 1,700%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Cytokinetics experienced a more modest increase of around 900% during the same period, indicating a more conservative growth strategy.
Alnylam's expenses peaked in 2023, reaching nearly 800% of its 2014 levels, while Cytokinetics saw its highest expenses in 2022, with a slight dip in 2023. These trends highlight the differing approaches of these companies in managing operational costs amidst evolving market dynamics. Investors and industry analysts should consider these financial strategies when evaluating the long-term potential of these biotech firms.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Alnylam Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Mesoblast Limited
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Cytokinetics, Incorporated
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: Cytokinetics, Incorporated vs Perrigo Company plc